Inhibrx Biosciences/$INBX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Inhibrx Biosciences
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
- Ticker
- $INBX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 110
- Headquarters
- La Jolla, United States
- Website
- inhibrx.com
INBX Metrics
BasicAdvanced
$1.1B
-
-$8.88
3.52
-
Price and volume
Market cap
$1.1B
Beta
3.52
52-week high
$155.29
52-week low
$57.30
Average daily volume
275K
Financial strength
Current ratio
5.067
Quick ratio
4.756
Long term debt to equity
-3.381
Total debt to equity
-3.428
Interest coverage (TTM)
-8.21%
Profitability
EBITDA (TTM)
-125.604
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-43.61%
Return on equity (TTM)
-1,773.60%
Valuation
Price to book
-19.93
Price to tangible book (TTM)
-19.93
Price to free cash flow (TTM)
-8.471
Free cash flow yield (TTM)
-11.80%
Free cash flow per share (TTM)
-8.473
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-16.12%
3-year earnings per share growth (CAGR)
17.56%
What the Analysts think about INBX
Analyst ratings (Buy, Hold, Sell) for Inhibrx Biosciences stock.
Analyst projections of the future price of Inhibrx Biosciences stock.
Bulls say / Bears say
INBRX-106 showed a sizeable efficacy signal in a randomised head-and-neck cancer study: confirmed response was 48.3% with the combination versus 26.5% with pembrolizumab alone, while median progression-free survival was 9.6 versus 4.9 months. The result gives the programme a potential route into a larger confirmatory trial. (Reuters, Inhibrx Biosciences)
Ozekibart has a regulatory catalyst in a rare cancer with no approved systemic treatment: the FDA accepted its chondrosarcoma application and set an April 2027 decision date. The supporting randomised trial more than doubled median progression-free survival versus placebo. (PR Newswire)
Ozekibart also has an early signal in heavily pre-treated colorectal cancer, with a 20% response rate, median progression-free survival of 5.5 months and disease control in 87% of evaluable patients. If confirmed in further studies, this could broaden the drug's opportunity beyond chondrosarcoma. (Transcenta)
The encouraging INBRX-106 result rests on a small Phase 2 dataset: only 63 patients were evaluable, including 19 HPV-positive patients. The estimates may shift as the company expands the study and tests the treatment in a larger confirmatory trial. (Inhibrx Biosciences)
Ozekibart carries a serious liver-safety risk: one hepatotoxicity-related death occurred in its chondrosarcoma trial before risk controls were introduced. The reported mitigation relied on excluding patients with severe liver impairment and close monitoring, which may constrain use and requires continued vigilance. (Healio)
Inhibrx remains loss-making and has no recent product revenue: it reported a $36.7 million second-quarter net loss and held $176.3 million in long-term debt at June 2026. Continued trial and launch spending could make further financing necessary, with potential dilution or added debt costs. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
INBX Financial Performance
Revenues and expenses
INBX Earnings Performance
Company profitability
Upcoming events
No upcoming events
INBX News
AllArticlesVideos
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
MarketBeat4 weeks ago
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Benzinga2 months ago
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Reuters2 months ago
Funds containing INBX
Fund name | Fund size | $INBX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.07% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.07% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.